FDA sets June date for latest review of Merck’s last-ditch antibioticThe FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new Share XFDA sets June date for latest review of Merck’s last-ditch antibiotichttps://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
InsightRX pens antibiotic deal for its precision dosing softwareA cloud-based system that makes drug dosing more personalised and precise – developed by InsightRX – is to Share XInsightRX pens antibiotic deal for its precision dosing softwarehttps://pharmaphorum.com/news/insightrx-pens-antibiotic-deal-for-its-precision-dosing-software/
SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers AnnouncedSMi’s 22nd Annual Superbugs & Superdrugs Conference Share XSMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers Announcedhttps://pharmaphorum.com/partner-content/smis-22nd-annual-superbugs-superdrugs-conference-2020-speakers-announced/
Still too little progress on antibiotic resistance, says O’Neill report updateThe O’Neill report on antimicrobial resistance in 2016 generated headlines around the world warning that once-trivial infections may Share XStill too little progress on antibiotic resistance, says O’Neill report updatehttps://pharmaphorum.com/news/still-too-little-progress-on-antibiotic-resistance-says-oneill-report-update/
FDA okays Nabriva’s novel antibiotic Xenleta for pneumoniaIreland-headquartered biotech Nabriva has picked up its first product approval, getting an FDA okay for antibiotic Xenleta as Share XFDA okays Nabriva’s novel antibiotic Xenleta for pneumoniahttps://pharmaphorum.com/news/fda-okays-nabrivas-novel-antibiotic-xenleta-for-pneumonia/
Merck gets FDA nod for new antibiotic, but says use with careThe FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have Share XMerck gets FDA nod for new antibiotic, but says use with carehttps://pharmaphorum.com/news/merck-gets-fda-nod-for-new-antibiotic-but-says-use-with-care/
Superbugs & Superdrugs USASuperbugs & Superdrugs USA November 12 – 13, 2018 New Jersey, USA http://www.superbugs-usa.com/pharmaphorumWL To address the ever-growing Share XSuperbugs & Superdrugs USAhttps://pharmaphorum.com/events/superbugs-superdrugs-usa/
W. J. Wiess and A.S. Lynch invitation to Superbugs & Superdrugs USASMi Group reports: William J. Weiss – University of North Texas Health Science Center and Anthony Simon Lynch Share XW. J. Wiess and A.S. Lynch invitation to Superbugs & Superdrugs USAhttps://pharmaphorum.com/partner-content/w-j-wiess-and-a-s-lynch-invitation-to-superbugs-superdrugs-usa/